CA3263975A1 - INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS - Google Patents

INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS

Info

Publication number
CA3263975A1
CA3263975A1 CA3263975A CA3263975A CA3263975A1 CA 3263975 A1 CA3263975 A1 CA 3263975A1 CA 3263975 A CA3263975 A CA 3263975A CA 3263975 A CA3263975 A CA 3263975A CA 3263975 A1 CA3263975 A1 CA 3263975A1
Authority
CA
Canada
Prior art keywords
ngf
treatment
hearing loss
intranasal administration
sensorineural hearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3263975A
Other languages
English (en)
French (fr)
Inventor
Vanessa CASTELLI
Andrea Aramini
Laura Brandolini
Pasquale COCCHIARO
Tiziana ROMEO
Nicola DETTA
Lucia APPARENTE
Simone MATTIOLI
Franca CATTANI
Flavio Mantelli
Marcello Allegretti
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3263975A1 publication Critical patent/CA3263975A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3263975A 2022-08-05 2023-08-04 INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS Pending CA3263975A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22188990.0A EP4316505A1 (en) 2022-08-05 2022-08-05 Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP22188990.0 2022-08-05
PCT/EP2023/071698 WO2024028487A1 (en) 2022-08-05 2023-08-04 Intranasal administration of ngf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
CA3263975A1 true CA3263975A1 (en) 2024-02-08

Family

ID=82846594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3263975A Pending CA3263975A1 (en) 2022-08-05 2023-08-04 INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS

Country Status (7)

Country Link
EP (2) EP4316505A1 (https=)
JP (1) JP2025525989A (https=)
CN (1) CN119836297A (https=)
AU (1) AU2023317864A1 (https=)
CA (1) CA3263975A1 (https=)
IL (1) IL318657A (https=)
WO (1) WO2024028487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4659759A1 (en) * 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017120465A1 (en) * 2016-01-06 2017-07-13 Massachusetts Eye And Ear Infirmary Treating cochlear synaptopathy
WO2018140792A2 (en) * 2017-01-27 2018-08-02 Otonomy, Inc. Neurotrophin mutants for treating hearing loss and other otic disorders
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
CN119836297A (zh) 2025-04-15
EP4316505A1 (en) 2024-02-07
EP4565255A1 (en) 2025-06-11
IL318657A (en) 2025-03-01
AU2023317864A1 (en) 2025-02-13
WO2024028487A1 (en) 2024-02-08
JP2025525989A (ja) 2025-08-07

Similar Documents

Publication Publication Date Title
CA3263975A1 (en) INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS
EP4460036A4 (en) HEADPHONES
CA3263977A1 (en) INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS
CA3264840A1 (en) MICROPHONE ISOLATION STAND
HK40122674A (en) Intranasal administration of ngf for the treatment of sensorineural hearing loss
CA3266315A1 (en) Nerve Growth Factor (NGF) for the Treatment of Spasticity
EP4412245A4 (en) EARPHONES
EP4398598A4 (en) EARPHONES
HK40117061A (en) Azasetron for the treatment of sudden sensorineural hearing loss
IL315627A (en) Azasterone for the treatment of sudden sensorineural hearing loss
CN309813901S (en) Speaker
CA217747S (en) Hearing aid
CA3295036A1 (en) Gene therapy for hearing disorders
CN309796426S (en) Loudspeaker
HK40105381A (en) Methods for treating sensorineural hearing loss using otoferlin dual vector systems
CA3289976A1 (en) Rollator
AU2024362751A1 (en) Gene therapy for hearing loss and vestibular disorders
CA3291458A1 (en) Therapy
CA3271207A1 (en) Therapy
CA3296479A1 (en) Azasetron for the preservation of residual hearing following cochlear implantation
EM150096920001S (bg) Говорители
EM87775770001S (cs) Reproduktory (část -)
EM87275310001S (hr) Zvučnici (kao dio -)
EM87275310002S (lv) Skaļruņi (- daļa)
HK40045406B (en) Modular earphone

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250314

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250411

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250411

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250506

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250507

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250628

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250628